AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20477993 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation (Lt) for CRC liver metastases
Number of subjects: 0
Study 20477993 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat liver transplantation (Lt) for CRC liver metastases
Number of subjects: 0
Study 20477993 — intervention group
Group type: COMPARATOR
Intervention: Liver transplantation (Lt) for CRC liver metastases (prior to 1995)
Number of subjects: 0
Study 20478057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide (300 mg/m2) followed by GM-CSF + GV1001 vaccinations
Number of subjects: 40
Study 20478863 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting stent (ZES)
Number of subjects: 8314
Study 20484311 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric dimethylarginine (ADMA) levels in the highest quartile (> 0.84 mumol/l)
Number of subjects: 133
Study 20484311 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA as a predictor of MACE
Number of subjects: 133
Study 20484311 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA levels
Number of subjects: 133
Study 20484311 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular function measures (arterial compliance and flow-mediated vasodilatation)
Number of subjects: 133
Study 20484311 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI and walking time
Number of subjects: 133
Study 20484443 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (200 IU daily for 1 year)
Number of subjects: 500
Study 20484456 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 long-chain polyunsaturated fatty acids (LCPUFAs) intake
Number of subjects: 2412
Study 20484456 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 2412
Study 20484456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intake of n-3 LCPUFAs (< approximately 0.30 g/d)
Number of subjects: 2412
Study 20484485 — intervention group
Group type: EXPERIMENTAL
Intervention: TT genotype
Number of subjects: 26
Study 20484485 — intervention group
Group type: COMPARATOR
Intervention: AA genotype
Number of subjects: 26
Study 20484486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 21
Study 20484542 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional left ventricular function assessment
Number of subjects: 356
Study 20487048 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day)
Number of subjects: 121
Study 20488302 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25-29.9 kg/m²)
Number of subjects: 34309
Study 20488302 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥30 kg/m²)
Number of subjects: 34309
Study 20488302 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants becoming obese during the first 60 months
Number of subjects: 34309
Study 20488302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic risk associated with BMI changes
Number of subjects: 34309
Study 20488302 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI increase of 1 kg/m²
Number of subjects: 34309
Study 20489056 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomy
Number of subjects: 1
Study 20489056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rag1 mutations
Number of subjects: 1
Study 20489056 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymus dysplasia
Number of subjects: 1
Study 20489056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rag deficiency phenotype
Number of subjects: 1
Study 20489392 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation of the quadriceps femoris muscle, 2-3 times a week for 6 weeks, in addition to an exercise program.
Number of subjects: 64
Study 20489392 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation of the quadriceps femoris muscle.
Number of subjects: 64
Study 20489620 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (dose escalation)
Number of subjects: 0
Study 20489620 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of imatinib dose to achieve a target imatinib plasma level
Number of subjects: 0
Study 20489620 — intervention group
Group type: COMPARATOR
Intervention: Standard imatinib dosing
Number of subjects: 0
Study 20491740 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU vitamin D3 once daily for 12 months
Number of subjects: 94
Study 20491740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 20491780 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (1.3 mg/m²)
Number of subjects: 13
Study 20491780 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (1.8 mg/m²)
Number of subjects: 13
Study 20491780 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (both doses)
Number of subjects: 13
Study 20492667 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking Action Together intervention
Number of subjects: 0
Study 20494615 — intervention group
Group type: EXPERIMENTAL
Intervention: 1987 survey
Number of subjects: 1000
Study 20494615 — intervention group
Group type: EXPERIMENTAL
Intervention: 1995 survey
Number of subjects: 1000
Study 20494615 — intervention group
Group type: EXPERIMENTAL
Intervention: 2007 survey
Number of subjects: 1000
Study 20494998 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI) at ages 20 and 50 years and at baseline
Number of subjects: 142982
Study 20494998 — intervention group
Group type: COMPARATOR
Intervention: Ever smoking
Number of subjects: 142982
Study 20494998 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption (drinks/week)
Number of subjects: 142982
Study 20496155 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Number of subjects: 10
Study 20497573 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 80
Study 20497573 — intervention group
Group type: COMPARATOR
Intervention: Light massage control
Number of subjects: 80
Study 20497785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity intervention (IMPACT study)
Number of subjects: 717
Study 20501469 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe oligozoospermia (SO)
Number of subjects: 90
Study 20501469 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent spontaneous abortion (RSA)
Number of subjects: 90
Study 20501469 — intervention group
Group type: COMPARATOR
Intervention: Healthy sperm donors (SD)
Number of subjects: 90
Study 20501583 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lens distance glasses
Number of subjects: 606
Study 20501583 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 606
Study 20501690 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery (GBP)
Number of subjects: 20
Study 20501690 — intervention group
Group type: COMPARATOR
Intervention: Diet-induced equivalent weight loss
Number of subjects: 20
Study 20502869 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive regional transcranial oxygen saturation (rSO(2))
Number of subjects: 22
Study 20502869 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive brain tissue oxygen pressure (PbrO(2))
Number of subjects: 22
Study 20504975 — intervention group
Group type: EXPERIMENTAL
Intervention: Males in late puberty (mean +/- SE: 1955 +/- 70 kcal)
Number of subjects: 204
Study 20504975 — intervention group
Group type: EXPERIMENTAL
Intervention: Females in late puberty (1388 +/- 68 kcal)
Number of subjects: 204
Study 20504975 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall energy intake by males
Number of subjects: 204
Study 20504975 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake adjusted for fat-free mass, fat mass, height, overweight status, race, and meal instruction
Number of subjects: 204
Study 20505894 — intervention group
Group type: EXPERIMENTAL
Intervention: pT3 patients with minimal extrathyroidal extension
Number of subjects: 347
Study 20505894 — intervention group
Group type: COMPARATOR
Intervention: pT4a patients with extensive extrathyroidal growth
Number of subjects: 347
Study 20507207 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Number of subjects: 673
Study 20507207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 673
Study 20507945 — intervention group
Group type: EXPERIMENTAL
Intervention: CTD-APAH
Number of subjects: 641
Study 20507945 — intervention group
Group type: COMPARATOR
Intervention: SSc-APAH
Number of subjects: 641
Study 20508186 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels measured on admission
Number of subjects: 362
Study 20508619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 400 mg/m(2)
Number of subjects: 25
Study 20508619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 500 mg/m(2)
Number of subjects: 25
Study 20508619 — intervention group
Group type: EXPERIMENTAL
Intervention: VDCR (Bortezomib, Dexamethasone, Cyclophosphamide, Lenalidomide)
Number of subjects: 25
Study 20510210 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 760
Study 20510214 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial salvage index (MSI) > median
Number of subjects: 208
Study 20510214 — intervention group
Group type: COMPARATOR
Intervention: Myocardial salvage index (MSI) < median
Number of subjects: 208
Study 20511445 — intervention group
Group type: COMPARATOR
Intervention: Lp(a) quintiles 2-5 vs quintile 1
Number of subjects: 26746
Study 20511445 — intervention group
Group type: COMPARATOR
Intervention: Nonfasting women Lp(a) quintiles 2-5 vs quintile 1
Number of subjects: 26746
Study 20511445 — intervention group
Group type: COMPARATOR
Intervention: Lp(a) <10 mg/L and Hb A(1c) <5%
Number of subjects: 26746
Study 20511445 — intervention group
Group type: COMPARATOR
Intervention: Nonfasting Danish men and women Lp(a) quintiles 2-5 vs quintile 1
Number of subjects: 26746
Study 20511662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate risk group (with at least one of: unmutated IGHV genes and/or IGHV3-21 usage, 11q deletion, β-2 microglobulin greater than 4 mg/L)
Number of subjects: 250
Study 20511662 — intervention group
Group type: EXPERIMENTAL
Intervention: Good risk group (with none of the above and mutated IGHV genes)
Number of subjects: 250
Study 20511662 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor risk group (with known TP53 loss of greater than 10%)
Number of subjects: 250
Study 20511662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-low risk (one risk factor)
Number of subjects: 250
Study 20511662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-high risk (2 or 3 risk factors)
Number of subjects: 250
Study 20516271 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg once-daily lamivudine (3TC) for children below 17 kg
Number of subjects: 49
Study 20516271 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg once-daily lamivudine (3TC) for children over 17 kg
Number of subjects: 49
Study 20516271 — intervention group
Group type: COMPARATOR
Intervention: Didanosine-lamivudine-efavirenz treatment
Number of subjects: 49
Study 20517912 — intervention group
Group type: EXPERIMENTAL
Intervention: LiDCO Plus monitor (calibrated)
Number of subjects: 20
Study 20517912 — intervention group
Group type: EXPERIMENTAL
Intervention: FloTrac-Vigileo monitor (uncalibrated)
Number of subjects: 20
Study 20518811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide added to mealtime insulin
Number of subjects: 1297
Study 20519658 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody positive subjects (GAD-65 and IA-2 autoantibodies)
Number of subjects: 1206
Study 20519658 — intervention group
Group type: COMPARATOR
Intervention: Antibody negative subjects
Number of subjects: 1206
Study 20519661 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 1846
Study 20519661 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (BA)
Number of subjects: 1846
Study 20519661 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1846
Study 20521331 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan Hand Questionnaire (MHQ)
Number of subjects: 128
Study 20522711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibril-reactive, amyloidolytic murine IgG1 mAb 11-1F4 labeled with I-124, infused with less than 1 mg (∼ 74 MBq) of GMP-grade antibody.
Number of subjects: 18
Study 20523092 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 70 mg/m(2) on days 1 and 15, irinotecan 100 mg/m(2) on days 8 and 22, capecitabine (dose levels 1-5, between 800 and 1,600 mg/m(2)) on days 1-29 every 5 weeks.
Number of subjects: 23
Study 20523092 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine at the recommended dose of 1,400 mg/m(2) daily.
Number of subjects: 23
Study 20524979 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals (control group)
Number of subjects: 0
Study 20524979 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray platelet syndrome (GPS) patients
Number of subjects: 0
Study 20525721 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodality therapy (induction chemotherapy with cisplatin 75 mg·m⁻² and pemetrexed 500 mg·m⁻², followed by extrapleural pneumonectomy and post-operative radiotherapy at 54 Gy, 30 fractions)
Number of subjects: 58
Study 20529243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 50
Study 20529243 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (20 mg/day)
Number of subjects: 50
Study 20529243 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (simvastatin and ezetimibe)
Number of subjects: 50
Study 20529376 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted cardiac rehabilitation (CR) intervention for 6 months
Number of subjects: 43
Study 20530034 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat 1.0-2.5 mg t.i.d. titrated according to systemic systolic blood pressure (SBP)
Number of subjects: 75
Study 20530034 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 75
Study 20530048 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg·m⁻²) plus valproic acid
Number of subjects: 45
Study 20530048 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 45
Study 20530284 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (RIT) using yttrium-90-ibritumomab-tiuxetan (15 MBq [0.4 mCi]/kg) with reduced-intensity conditioning (RIC) using fludarabine (90 mg/m(2)) and 2 Gy total body irradiation followed by allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 40
Study 20534736 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric measurement using semiautomated algorithm
Number of subjects: 48
Study 20534736 — intervention group
Group type: COMPARATOR
Intervention: Unidimensional measurement
Number of subjects: 48
Study 20534744 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood condition
Number of subjects: 25
Study 20534744 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25
Study 20534744 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal use of food for emotion regulation
Number of subjects: 25
Study 20534744 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal use of restriction, pressure to eat, and use of foods as a reward
Number of subjects: 25
Study 20535444 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic control intervention
Number of subjects: 0
Study 20535444 — intervention group
Group type: COMPARATOR
Intervention: Control group (type 2 diabetes)
Number of subjects: 0
Study 20535449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of bladder wall thickness (BWT) in women with detrusor overactivity (DO)
Number of subjects: 247
Study 20535449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of bladder wall thickness (BWT) for urgency urinary incontinence
Number of subjects: 247
Study 20535449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of bladder wall thickness (BWT) for 'pure DO'
Number of subjects: 247
Study 20535449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of bladder wall thickness (BWT) for 'all DO'
Number of subjects: 247
Study 20537128 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI)
Number of subjects: 2054
Study 20537130 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI)
Number of subjects: 30
Study 20537292 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 22
Study 20537292 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (CRS without immune dysfunction)
Number of subjects: 22
Study 20538956 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial biogenesis and antioxidant defense responses in critically ill patients.
Number of subjects: 16
Study 20538956 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial morphology and protein content in critically ill patients.
Number of subjects: 16
Study 20538956 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA content of peroxisome proliferator-activated receptor γ coactivator 1-α in critically ill patients.
Number of subjects: 16
Study 20538956 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese superoxide dismutase in critically ill patients.
Number of subjects: 16
Study 20538956 — intervention group
Group type: EXPERIMENTAL
Intervention: Microarray analysis and phosphorylated (energy) metabolites in critically ill patients.
Number of subjects: 16
Study 20538985 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial lens bacterial bioburden
Number of subjects: 205
Study 20538985 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 205
Study 20538985 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal staining (mild or greater)
Number of subjects: 205
Study 20538985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative probability of remaining CIE free
Number of subjects: 205
Study 20539305 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 425
Study 20539305 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine use
Number of subjects: 425
Study 20539305 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 425
Study 20540778 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5
Number of subjects: 57000
Study 20542323 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 20542776 — intervention group
Group type: EXPERIMENTAL
Intervention: NexStent and Filterwire EX/EZ devices
Number of subjects: 454
Study 20542776 — intervention group
Group type: EXPERIMENTAL
Intervention: NexStent and Filterwire EX/EZ devices (asymptomatic patients)
Number of subjects: 454
Study 20542776 — intervention group
Group type: EXPERIMENTAL
Intervention: NexStent and Filterwire EX/EZ devices (symptomatic patients)
Number of subjects: 454
Study 20542776 — intervention group
Group type: EXPERIMENTAL
Intervention: NexStent and Filterwire EX/EZ devices (patients <80 years)
Number of subjects: 454
Study 20542776 — intervention group
Group type: EXPERIMENTAL
Intervention: NexStent and Filterwire EX/EZ devices (patients >=80 years)
Number of subjects: 454
Study 20542797 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Petal paclitaxel-eluting bifurcation stent
Number of subjects: 28
Study 20545713 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid administration (200 mL of hydroxyethyl starch, HES 130/0.4)
Number of subjects: 20
Study 20545869 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated atrial threshold measurements
Number of subjects: 691
Study 20545869 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated RV threshold measurements
Number of subjects: 691
Study 20545869 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold tracking feature On
Number of subjects: 691
Study 20545869 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced ventricular pacing
Number of subjects: 691
Study 20545869 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced atrial pacing
Number of subjects: 691
Study 20545869 — intervention group
Group type: EXPERIMENTAL
Intervention: High impedance leads (> or =1,000 ohms)
Number of subjects: 691
Study 20545869 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in device size (1-cc)
Number of subjects: 691
Study 20546561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting AEA levels
Number of subjects: 41
Study 20546561 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fasting AEA levels after lunch with beer
Number of subjects: 41
Study 20546561 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fasting AEA levels after lunch with alcohol-free beer
Number of subjects: 41
Study 20546561 — intervention group
Group type: EXPERIMENTAL
Intervention: AEA levels
Number of subjects: 41
Study 20546561 — intervention group
Group type: EXPERIMENTAL
Intervention: OEA levels
Number of subjects: 41
Study 20547978 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding by +1,250 kcal/day (45% fat) for 28 days
Number of subjects: 36
Study 20549047 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK) with mitomycin-C (MMC)
Number of subjects: 60
Study 20549827 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (letrozole or exemestane)
Number of subjects: 30
Study 20549827 — intervention group
Group type: COMPARATOR
Intervention: Baseline wrist ultrasound
Number of subjects: 30
Study 20549827 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported symptoms
Number of subjects: 30
Study 20550679 — intervention group
Group type: EXPERIMENTAL
Intervention: 166Ho-PLLA-MS radioembolization (166Ho-RE)
Number of subjects: 15
Study 20550691 — intervention group
Group type: EXPERIMENTAL
Intervention: 10s epochs
Number of subjects: 102
Study 20550691 — intervention group
Group type: EXPERIMENTAL
Intervention: 60s epochs
Number of subjects: 102
Study 20550698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 49
Study 20550698 — intervention group
Group type: COMPARATOR
Intervention: Hydroxycobalamin (given to some patients before HBO)
Number of subjects: 49
Study 20550701 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum neutrophil measurements
Number of subjects: 488